HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
INO
Inovio Pharmaceuticals, Inc.
There isn't enough reported data to score INO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
INO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
INO's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
INO PE Valuation
INO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
INO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect INO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
INO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.67 | +$1.88 |
| Q2 2026 | -$1.04 | +$1.53 |
| Q1 2026 | -$1.58 | +$1.57 |
| Q4 2025 | -$1.81 | +$2.14 |
| Q3 2025 | -$2.55 | +$1.89 |
| Q2 2025 | -$2.57 | +$2.54 |
| Q1 2025 | -$3.15 | +$2.33 |
| Q4 2024 | -$3.95 | +$2.14 |
INO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over INO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over INO on profitability, with a higher operating margin.
INO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $117K | +14% |
| Q2 2024 | $100.8K | -55% |
| Q4 2023 | $102.7K | -18% |
| Q3 2023 | $388.4K | -96% |
| Q2 2023 | $226K | -71% |
| Q1 2023 | $114.9K | -42% |
| Q4 2022 | $124.7K | -85% |
| Q3 2022 | $9.2M | +3038% |
INO's revenue is growing: $298,901 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6532% | N/A |
| Q1 2025 | -38337% | N/A |
| Q4 2024 | -17411% | +9276 points |
| Q2 2024 | -32946% | -16554 points |
| Q4 2023 | -26686% | +18191 points |
| Q3 2023 | -9153% | -8762 points |
| Q2 2023 | -16392% | -3116 points |
| Q1 2023 | -38238% | -2205 points |
INO's operating margin was −6532% last quarter, up 20154 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over INO on cash generation, producing positive trailing cash flow while its opponent burns cash.
INO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$6.4M |
| Q2 2026 | -$18M | +$2.8M |
| Q1 2026 | -$21.6M | +$5.3M |
| Q4 2025 | -$19.5M | +$165.9K |
| Q3 2025 | -$21.6M | +$5.8M |
| Q2 2025 | -$20.8M | +$7.8M |
| Q1 2025 | -$26.9M | +$1.9M |
| Q4 2024 | -$19.7M | +$6.6M |
INO has burned cash in almost every quarter: −$74M over the past year, against −$89M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over INO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
INO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +17M shares |
| 1 year | +154% | +59.8M shares |
| 3 years | +358% | +77.1M shares |
| 5 years | +485% | +81.8M shares |
INO has 99M diluted shares, up 154% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
INO Net Leverage
INO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
INO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.5 | Neutral |
| Stochastic | 32.9 | Neutral |
INO's weekly RSI is 57 (neutral) and its Stochastic is 33 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
INO PE vs Healthcare Sector
INO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
INO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.08 | 35% above |
| 20 week MA | $1.10 | 33% above |
| 50 week MA | $1.35 | 8.1% above |
| 100 week MA | $1.67 | 13% below |
| 200 week MA | $4.98 | 71% below |
INO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
INO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.1 | $123.1 | +207% |
| 2021 | $123.1 | $73.0 | -41% |
| 2022 | $73.0 | $18.4 | -75% |
| 2023 | $18.4 | $6.12 | -67% |
| 2024 | $6.12 | $1.87 | -69% |
| 2025 | $1.87 | $2.29 | +22% |
| 2026 YTD | $2.29 | $1.46 | -36% |
INO has the edge over HIMS on returns for 2026, with the stronger performance.